AZTR logo

AZITRA INC

AZTRNYSE AMERICAN
🏆 #5370 by market capEarnings Nov 11US Equity
$0.13▼ $0.03 (−24.51%)
Live
🔔
Track AZTR
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 24.5%
7d▼ 24.4%
14d▼ 25.6%
30d▼ 25.8%
ytd▼ 51.8%
1y▼ 81.4%
🏦Market Cap
$1M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
44
Weak

Trading Snapshot

Day Range
$0.13 – $0.13
52-Week Range
$0.10 – $1.09
Volume
$2.16B
Avg Volume
$1.49B
Shares Outstanding
10.7M
Next Earnings
Nov 28, 2026

Fundamentals Snapshot

Annual Revenue
$367,445
Last Q Revenue
$90,620
P/E Ratio
-0.1
P/S Ratio
0.0x
EPS (TTM)
$-0.64
Dividend Yield
0.00%
Dilution (1yr)
+838.0%

Why Investors Own AZTR

  • ✓High-growth profile — revenue up -6.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 46% gross margin and 7% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AZTR logo

AZITRA INC

AZTR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▼ −0.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▲ +8.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.7M▲ +838.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$2M YoY
StockOtter · stockotter.space

About AZITRA INC

Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Barron’s·2h ago

AZITRA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift AZTR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

AZITRA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.